Data Page | Published:

3Q13—IPOs continue to roar

Nature Biotechnology volume 31, page 955 (2013) | Download Citation

Public markets continued their swoon over biotech. Up 21% in 3Q13, the BioCentury 100 surpassed on October 1 its all-time high set in March 2000. Public offerings also continued their roll, new issues raising $1.3 billion ($2.9 billion since January now approaching 2007's $3.1-billion high) and follow-ons up 24% from 3Q12. Overall funding (excluding partnership) declined by 12% to $11.5 billion (compared with 3Q12), largely due to fewer jumbo debt deals. Venture money decreased 33% to $1.2 billion from a year ago.

Box 1: Stock market performance
Box 2: Notable 3Q12 deals
Box 3: Global biotech industry financing
Box 4: Global biotech initial public offerings
Box 5: Global biotech venture capital investment

Author information

Affiliations

  1. Walter Yang is Research Director at BioCentury.

    • Walter Yang

Authors

  1. Search for Walter Yang in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.2745

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing